iBio Inc (IBIO) 股息

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2008-08-18. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. The company has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.